Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent

Vollmer, Olivier; Tacquard, Charles-Ambroise; Dieudonné, Yannick; Nespola, Benoît; Sattler, Laurent; Grunebaum, Lélia; Gies, Vincent; Radosavljevic, Mirjana; Kaeuffer, Charlotte; Hansmann, Yves; Weber, Jean-Christophe; Martin, Thierry; Arnaud, Laurent; Morel, Olivier; Guffroy, Aurélien; Collange, Olivier; Mertès, Paul-Michel; Korganow, Anne‐Sophie; Delabranche, Xavier

doi:10.1016/j.autrev.2021.102822

Cited by 29 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 48 studies were eligible for a complete analysis of their results [ 6 •, 9 , 10 , 11 , 12 , 13 ••, 14 – 55 ]. Only two reports were cohort studies with repeated assays for aPL after one month for the first [ 13 ••] and between 3 and 6 months for the second [ 52 ]. Eight publications were case reports from two to six patients [ 9 , 17 , 30 , 33 , 34 , 36 , 38 , 51 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

et al. 2021

View full text Add to dashboard Cite

Purpose of Review COVID-19 patients have a procoagulant state with a high prevalence of thrombotic events. The hypothesis of an involvement of antiphospholipid antibodies (aPL) has been suggested by several reports. Here, we reviewed 48 studies investigating aPL in COVID-19 patients. Recent Findings Prevalence of Lupus Anticoagulant (LA) ranged from 35% to 92% in ICU patients. Anti-cardiolipin (aCL) IgG and IgM were found in up to 52% and up to 40% of patients respectively. Anti-β 2 -glycoprotein I (aβ 2 -GPI) IgG and IgM were found in up to 39% and up to 34% of patients respectively. Between 1% and 12% of patients had a triple positive aPL profile. There was a high prevalence of aβ 2 -GPI and aCL IgA isotype. Two cohort studies found few persistent LA but more persistent solid phase assay aPL over time. Summary aPL determination and their potential role is a real challenge for the treatment of this disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“…A second study performed aPL assays between 3 and 6 months after a first positive LA test [ 52 ]. A total of 42 patients among 79 patients initially tested positive for LA were tested again.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Some have found no consistent association of antiphospholipid antibodies and thrombosis or disease severity [ 46 , 49 , 51 , 53 , 64 , 69 , 71 ]. Whether detected at the time of first patient presentation or shortly thereafter, such antibody status is time-accrued, maximizes in over 1 month after infection onset, and tends to be transient [ 49 , 68 , 70 ]. The timing of antibody detection therefore must be considered in comparing one study to another.…”

Section: Antiphospholipid Antibodies and Covid-19 Infectionmentioning

confidence: 99%

“…Some studies find a particular association of severe disease with the presence of IgA antiphospholipid antibodies [ 42 , 57 ]. Among patients with lupus anticoagulant, one study of critically ill patients found an association of IgM anticardiolipin antibodies with thrombosis [ 70 ]. Antibodies to phosphatidyl serine/prothrombin complex and/or prothrombin appear to be much less common in some but not all studies [ 68 , 69 , 73 ].…”

Section: Antiphospholipid Antibodies and Covid-19 Infectionmentioning

confidence: 99%

“…From the research detailed above, it is safe to say that a conclusive role of antiphospholipid antibodies in the course of COVID-19 is yet to be defined. The rise of antiphospholipid antibodies during COVID-19 infection must be seen in a larger context of the potential rise in autoantibodies generally [ 32 , 61 , 68 , 70 , 72 ].…”

Section: Antiphospholipid Antibodies and Covid-19 Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Cimolai

2021

SN Compr. Clin. Med.

View full text Add to dashboard Cite

Advanced SARS-CoV-2 infections not uncommonly associate with the occurrence of silent or manifest thrombotic events which may be found as focal or systemic disease. Given the potential complexity of COVID-19 illnesses, a multifactorial causation is likely, but several studies have focused on infection-induced coagulopathy. Procoagulant states are commonly found in association with the finding of antiphospholipid antibodies. The correlation of the latter with thrombosis and/or clinical severity remains controversial. Although measures of antiphospholipid antibodies most commonly include assessments for lupus anticoagulant, anticardiolipin, and anti-ß2-glycoprotein-I antibodies, lesser common antibodies have been detected, and there remains speculation that other yet undiscovered autoimmune thrombotic events may yet be found. The recent discovery of post-vaccination thromboses associated with platelet factor 4 antibody has created another level of concern. The pathogenesis of antiphospholipid antibodies and their role in COVID-19-related thrombosis deserves further attention. The multifactorial nature of thrombosis associated with both infection and vaccination should continue to be studied as new events unfold. Even if a cause-and-effect relationship is variable at best, such dedicated research is likely to generate other valuable insights that are applicable to medicine generally.

show abstract

Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt

et al. 2022

View full text Add to dashboard Cite

Background Coagulopathy is still a serious pattern of coronavirus-19 disease. We aimed to evaluate COVID-19-associated coagulopathy and multiple hemostatic markers in Egyptian patients. In addition, to assess coagulation acute phase reactants and its effect on the outcome. Methods The study included 106 COVID-19 patients, and 51 controls. All patients were positive for COVID-19 infection by nasopharyngeal swab for detection of viral RNA by real-time PCR. In addition to baseline data and radiological findings, the coagulation profile was done with special attention to Fibrinogen, d-dimer, Factor VIII, von Willebrand factor (VWF), Protein C, Protein S, Antithrombin III (ATIII) and Lupus anticoagulant (LA)-1 and 2. Results The results showed significantly higher VWF, d-dimer, and LA1 (screening) and LA2 (confirmation) in patients than a control group. Significantly higher d-dimer FVIII, VWF and LA1-2 were detected in the severe group. ATIII had high diagnostic accuracy in severity prediction. We found a significantly higher international randomized ratio (INR) and VWF among patients with thrombotic events. For prediction of thrombosis; VWF at cutoff > 257.7 has 83.3% sensitivity and 83.3% specificity. Conclusion Patients with COVID-19 infection are vulnerable to different forms of coagulopathy. This could be associated with poor outcomes. d-Dimer is a chief tool in diagnosis, severity evaluation but not thrombosis prediction. Early screening for this complication and its proper management would improve the outcome.

show abstract

Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent

Cited by 29 publications

References 19 publications

Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?

Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19

Assessment of COVID -19 associated coagulopathy and multiple hemostatic markers: a single center study in Egypt

Contact Info

Product

Resources

About